On the importance of estimating renal function for cardiovascular risk assessment

Julian Segura, Luis M. Ruilope, Alberto Zanchetti

Research output: Contribution to journalArticle

Abstract

Microalbuminuria has been shown to predict an increased probability of suffering a cardiovascular event or death. It has also been shown to be decreased by antihypertensive therapy and in particular by drugs counteracting the effects of angiotensin II. In this issue of Journal of Hypertension data, from the LIFE study, are reported indicating for the first time that a decrease in urinary albumin excretion rate is accompanied by a significant decrease in cardiovascular events. This evidence is of great relevance because it constitutes the first evidence showing that regression of an intermediate end-point, microalbuminuria, ensures a better cardiovascular prognosis.

Original languageEnglish
Pages (from-to)1635-1639
Number of pages5
JournalJournal of Hypertension
Volume22
Issue number9
DOIs
Publication statusPublished - Sep 2004

    Fingerprint

Keywords

  • Arterial hypertension
  • Cardiovascular risk
  • LIFE study
  • Microalbuminuria

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this